FCA
MRTX

FinTrust Capital Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

FinTrust Capital Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7
Closed -$392 – 1320
2023
Q4 		$392 Hold
7
– – ﹤0.01% 1197
2023
Q3 		$291 Buy
+7
New +$250 ﹤0.01% 1186

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

FinTrust Capital Advisors's MRTX Position: Q1 2024 in Review

FinTrust Capital Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 7 shares — an estimated $392 sold.

FinTrust Capital Advisors first reported a position in MRTX in Q3 2023 and held it in 2 quarters. The position peaked at $392 in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • FinTrust Capital Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • FinTrust Capital Advisors sold 7 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $392.
  • FinTrust Capital Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2023 and held it in 2 quarters.
  • FinTrust Capital Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $392 in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on FinTrust Capital Advisors's 13F filing for Q1 2024, filed 2 May 2024.